Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer

Journal of Clinical Oncology

Volumn 33, Issue 12, 2015, Pages 1348-1355

  Scher, Howard I ^a,b   Heller, Glenn ^a   Molina, Arturo ^d   Attard, Gerhardt ^f,g   Danila, Daniel C ^a,b   Jia, Xiaoyu ^c   Peng, Weimin ^d   Sandhu, Shahneen K ^f,g   Olmos, David ^f,g   Riisnaes, Ruth ^f   McCormack, Robert ^d   Burzykowski, Tomasz ^h   Kheoh, Thian ^e   Fleisher, Martin ^a   Buyse, Marc ^h   De Bono, Johann S ^f,g  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^e JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g ROYAL MARSDEN HOSPITAL   (United Kingdom)

^h INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ALBUMIN; ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; DOCETAXEL; HEMOGLOBIN; LACTATE DEHYDROGENASE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ANDROSTANE DERIVATIVE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CELL COUNT; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; HUMAN CELL; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; BIOASSAY; BLOOD; CLINICAL TRIAL; METASTASIS; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TUMOR EMBOLISM; VERY ELDERLY;

ABIRATERONE ACETATE; ADULT; AGED; AGED, 80 AND OVER; ANDROSTENES; BIOMARKERS, TUMOR; ENDPOINT DETERMINATION; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84929413050     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.3487     Document Type: Article

References (37)

1. de Bono JS, Oudard S, Ozguroglu M, et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376:1147-1154, 2010
2. de Bono JS, Logothetis CJ, Molina A, et al: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005, 2011
3. Fizazi K, Scher HI, Molina A, et al: Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13:983-992, 2012
4. Kantoff PW, Higano CS, Shore ND, et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-422, 2010
5. Parker C, Nilsson S, Heinrich D, et al: Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213-223, 2013
6. Ryan CJ, Smith MR, de Bono JS, et al: Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138-148, 2013
7. Scher HI, Fizazi K, Saad F, et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187-1197, 2012
8. Pantel K, Brakenhoff RH, Brandt B: Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 8:329-340, 2008
9. Parkinson DR, Dracopoli N, Petty BG, et al: Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med 10:138, 2012
10. US Food and Drug Administration: CellSearch Circulating Tumor Cell Kit: K073338 - Premarket notification: Expanded indications for use - Metastatic prostate cancer. http://www.accessdata.fda.gov/cdrh-docs/pdf7/K073338.pdf
11. US Food and Drug Administration: CellSearch Epithelial Cell Kit/CellSpotter Analyzer: K031588. http://www.fda.gov/MedicalDevices/ProductsandMedical Procedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm081239.htm
12. Cohen SJ, Punt CJ, Iannotti N, et al: Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26:3213-3221, 2008
13. Cristofanilli M, Budd GT, Ellis MJ, et al: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781-791, 2004
14. de Bono JS, Scher HI, Montgomery RB, et al: Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14:6302-6309, 2008
15. Holzbeierlein J, Lal P, LaTulippe E, et al: Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164:217-227, 2004
16. Locke JA, Guns ES, Lubik AA, et al: Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 68:6407-6415, 2008
17. Attard G, Belldegrun AS, de Bono JS: Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int 96: 1241-1246, 2005
18. Attard G, Reid AH, Yap TA, et al: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26:4563-4571, 2008
19. Fleming MT, Morris MJ, Heller G, et al: Posttherapy changes in PSA as an outcome measure in prostate cancer clinical trials. Nat Clin Pract Oncol 3:658-667, 2006
20. Omlin A, Pezaro C, Mukherji D, et al: Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. Eur Urol 64:300-306, 2013
21. Scher HI, Halabi S, Tannock I, et al: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148-1159, 2008
22. Scher HI, Jia X, de Bono JS, et al: Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: A reanalysis of IMMC38 trial data. Lancet Oncol 10: 233-239, 2009
23. Danila DC, Morris MJ, de Bono JS, et al: Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 28:1496-1501, 2010
24. Reid AH, Attard G, Danila DC, et al: Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 28:1489-1495, 2010
25. Prentice RL: Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med 8:431-440, 1989
26. Armstrong AJ, Garrett-Mayer E, de Wit R, et al: Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 16:203-211, 2010
27. Halabi S, Small EJ, Kantoff PW, et al: Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21:1232-1237, 2003
28. Uno H, Cai T, Pencina MJ, et al: On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med 30:1105-1117, 2011
29. Grambsch PM, Therneau TM: Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81:515-526, 1994
30. Goldkorn A, Ely B, Quinn DI, et al: Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: A phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol 32:1136-1142, 2014
31. Goodman OB Jr, Symanowski JT, Loudyi A, et al: Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer. Clin Genitourin Cancer 9:31-38, 2011
32. Halabi S, Small EJ, Hayes DF, et al: Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: A nested study within CALGB 9583. J Clin Oncol 21:490-495, 2003
33. Halabi S, Lin CY, Kelly WK, et al: Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol 32:671-677, 2014
34. Smaletz O, Scher HI, Small EJ, et al: Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20:3972-3982, 2002
35. Buyse M, Molenberghs G, Burzykowski T, et al: The validation of surrogate endpoints in metaanalyses of randomized experiments. Biostatistics 1:49-67, 2000
36. Petrella M, Montaner J, Batist G, et al: The role of surrogate markers in the clinical development of antiretroviral therapy: A model for early evaluation of targeted cancer drugs. Cancer Invest 22:149-160, 2004
37. Sargent DJ, Wieand HS, Haller DG, et al: Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23:8664-8670, 2005